The role of IFN-gamma in tumor transplantation immunity and inhibition of chemical carcinogenesis (Q35084261)

6 August 2017

1 reference

title

The role of IFN-gamma in tumor transplantation immunity and inhibition of chemical carcinogenesis (English)

1 reference

6 August 2017

1 reference

Thomas Blankenstein

1

1 reference

PubMed ID

12633663

6 August 2017

Zhihai Qin

series ordinal

2

1 reference

6 August 2017

1 April 2003

1 reference

Current Opinion in Immunology

6 August 2017

1 reference

6 August 2017

15

1 reference

6 August 2017

148-154

1 reference

6 August 2017

2

1 reference

The molecular cell biology of interferon-gamma and its receptor

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

Cellular responses to interferon-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

Reciprocal regulation of polarized cytokine production by effector B and T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: A novel pathway of autocrine macrophage activation

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

Tumor rejection by disturbing tumor stroma cell interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

The role of IFN-gamma in the outcome of chlamydial infection

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

The central role of CD4(+) T cells in the antitumor immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

Differential requirement of perforin and IFN-gamma in CD8 T cell-mediated immune responses against B16.F10 melanoma cells expressing a viral antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

T cell-mediated tumor rejection displays diverse dependence upon perforin and IFN-gamma mechanisms that cannot be predicted from in vitro T cell characteristics.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

Decreased generation of anti-tumor immunity after intrasplenic immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

Cross-presentation, dendritic cells, tolerance and immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

Generation of tumor-associated cytotoxic T lymphocytes requires interleukin 4 from CD8(+) T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

Naive CD8(+) but not CD4(+) T cells induce maturation of dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

On cross-priming of MHC class I-specific CTL: rule or exception?

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

Autocrine Production of IL-10 Mediates Defective IL-12 Production and NF- B Activation in Tumor-Associated Macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

Virus clearance and immunopathology by CD8(+) T cells during infection with respiratory syncytial virus are mediated by IFN-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

Inhibition of methylcholanthrene-induced carcinogenesis by an interferon gamma receptor-dependent foreign body reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

Systemic deficits in transporter for antigen presentation (TAP)-1 or proteasome subunit LMP2 have little or no effect on tumor incidence

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

IRF family of transcription factors as regulators of host defense

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

Tumor Development after 3-Methylcholanthrene in Immunologically Deficient Athymic-Nude Mice

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

MCA Sarcomas Induced in scid Mice are More Immunogenic than MCA Sarcomas Induced in Congenic, Immunocompetent Mice

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900007-4

7 January 2021

10.1016/S0952-7915(03)00007-4

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12633663